BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Gazyva/Gazyvaro is an anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a CRR benefit in lupus ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License ...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal response benefit1 The filing application is based on data from the phase ...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal ...

Lunsumio (mosunetuzumab) was approved in the EU as an intravenous treatment for patients with relapsed or refractory follicular lymphoma (FL) in June, becoming the first drug in the class to reach ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Columvi® (glofitamab) in ...

STARGLO was intended as a confirmatory study for the conditional marketing authorisation of Columvi in the EU. Columvi, along with Lunsumio® (mosunetuzumab), is part of Roche's industry-leading ...

1月30日，罗氏公布2024年全年业绩，总营收达604.95亿瑞士法郎(约688.92亿美元)，同比增长7%(按固定汇率计算)。其中，制药业务 ...